Samsung Biologics and Eli Lilly announced a partnership to establish a new Gateway Labs site in Korea, aiming to accelerate drug discovery and development.
This collaboration signifies a significant expansion of R&D infrastructure in the APAC region, specifically South Korea. By partnering with a leading CDMO like Samsung Biologics, Eli Lilly gains access to advanced capabilities and local expertise, potentially streamlining its drug development pipeline. The presence of LGL in Korea could foster innovation, attract further investment in the local biotech ecosystem, and contribute to the growth of South Korea as a key hub for pharmaceutical research and manufacturing in Asia.
Samsung Biologics partners with Eli Lilly to establish a new Gateway Labs site.
The new site will be located in Korea, enhancing APAC's R&D infrastructure.
This collaboration aims to accelerate drug discovery and development processes.
This partnership directly impacts South Korea's position as a growing biotech hub in APAC. It enhances the region's capabilities in drug discovery and development, potentially leading to more localized pharmaceutical innovation and manufacturing. The collaboration strengthens the ties between global pharmaceutical giants and APAC CDMOs.
The new site will be located in Korea, enhancing APAC's R&D infrastructure.
Samsung Biologics partners with Eli Lilly to establish a new Gateway Labs site.
Sign in to save notes on signals.
Sign In